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Cyclic Neutropenia (CN) is characterized by recurrent infections, fever, oral ulcerations, and severe periodontitis as result of the
reduced host defences. The previous studies have established the eﬀectiveness of recombinant granulocyte colony-stimulating
factor (GCSF) to increase the number and the function of neutrophils in the peripheral blood in this disease. In a 20-year-old
Caucasian female with a diagnosis of cyclic neutropenia, oral clinical examination revealed multiple painful ulcerations of the
oral mucosa, poor oral hygiene conditions, marginal gingivitis, and moderate periodontitis. The patient received a treatment
with G-CSF (Pegﬁlgrastim, 6mg/month) in order to improve her immunological status. Once a month nonsurgical periodontal
treatment was carefully performed when absolute neutrophil count (ANC) was ≥500/μL. The treatment with G-CSF resulted in a
rapid increase of circulating neutrophils that, despite its short duration, leaded to a reduction in infection related events and the
resolution of the multiple oral ulcerations. The disappearance of oral pain allowed an eﬃcacy nonsurgical treatment and a normal
tooth brushing that determined a reduction of probing depth (PD ≤ 4mm) and an improvement of the oral hygiene conditions
recorded at 6-month follow-up.
Copyright © 2009 Sergio Matarasso et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Neutrophils play a critical role in the host defence mech-
anism against bacterial infections [1]. There are 3 general
guidelines used to classify the severity of neutropenia based
on the absolute neutrophil count (ANC) measured in cells
per microliter of blood:
(i) mild neutropenia (1000 ≤ ANC < 1500)—minimal
risk of infection,
(ii) moderate neutropenia (500 ≤ ANC < 1000)—
moderate risk of infection,
(iii) severe neutropenia (ANC < 500)—severe risk of
infection.
The above mentioned ranges were developed in Cau-
casians. In colored population, mild neutropenia is a normal
phenomenon, and neutropenia in this population is more
properly deﬁned as ANC < 1200. Higher cutoﬀsm a yl e a d
to overdiagnosis of neutropenia in the colored population
[2]. The clinical consequence of the disease is an increased
infective diathesis proportional to the severity of the neu-
tropenia. Several forms of neutropenia (agranulocytosis,
familiar benign neutropenia, severe chronic neutropenia)
can be found associated with oral manifestations. Severe
chronic neutropenia is characterized by a selective decrease
in circulating neutrophils and includes a heterogeneous
group of haematological diseases divided into three main
syndromes: idiopathic neutropenia, congenital forms of
neutropenia, and cyclic neutropenia.
The present paper is aimed at evaluating the eﬃcacy of
a non surgical periodontal treatment associated with G-CSF
therapy in a patient suﬀering from cyclic neutropenia (CN)2 International Journal of Dentistry
Figure 1: Ulceration of tongue.
associated with oral manifestations and periodontal disease.
Written informed consent was obtained by the patient and
the authors declare no conﬂict of interest related to this
paper.
2. Case Presentation
A 20-year-old Caucasian female with diagnosis of CN was
referred by the Department of Immunology and Allergology,
to the Department of Periodontology of the University of
Naples Federico II, Italy. Anamnesis revealed that since the
ﬁrst year of life the patient has been suﬀering from repeated
phases of fever and oral ulcerations, associated with pain and
lymphadenopathy. During childhood and adolescence the
patient had repeated admissions to the hospital, but CN was
diagnosed only in September 2007. The haematological ﬁnd-
ings (complete laboratory work-up) showed the neutropenic
phase recurred approximately every 21 days. The lowest
neutrophil count was 0,20 × 103/μL. A light enlargement
of submandibular and cervical lymph nodes was revealed
by palpation and moreover fever (37,8
◦C) sinusitis and
pharyngitis were recorded during the neutropenic phase. In
additionshereportedtobrushherteeththreetimesadaybut
during the neutropenic crisis oral hygiene was hindered by
pain due to oropharyngeal ulcerations (Figures 1, 2,a n d3).
Full Mouth Plaque Score (FMPS) and Full Mouth Bleeding
Score (FMBS), recorded on 6 sites per tooth, were 66.7%
and 64.8%, respectively (Figure 4). Periodontal examination
revealed a generalized increased probing depths (Figure 5).
No furcations were involved and no gingival recessions
were recorded. Tooth mobility was not present. An X-ray
examination revealed bone loss on interproximal aspect of
maxillary and mandibular teeth (Figure 6). A diagnosis of
moderate periodontitis as manifestation of systemic disease
was made.
Since September 2007 up till February 2008 the
patient received a systemic treatment with Prednisolone
10mg/dieo.s./7 days (Deltacortene, Bruno Farmaceutici)
during the neutropenia phases. The above therapy had a
minimum eﬀect on severity of oral ulcerations and produced
minimal improvement in ANC. At this regard pain and
burning determined poor oral hygiene conditions (FMPS =
41.3% and FMBS = 4.2%).
Figure 2: Ulceration of labial commissural.
Figure 3: Ulceration of lower lip.
In March 2008, the patient received a new treatment with
GCSFadministrationconsistingofsubcutaneousinjectionof
Pegﬁlgrastim 6mg (Neupopeg, Domp` e Biotec S.p.A., Italy)
once a month.
Periodontal treatment including oral hygiene instruc-
tions, scaling, root planning, and polishing was meticulously
carried out once a month when absolute neutrophil count
(ANC) was >1500/μL and for this reason prophylactic
antibiotic therapy was not prescribed. During neutropenic
cycles the patient was advised to rinse her mouth twice a
day with 0.2% chlorhexidine gluconate. A very high level
of compliance was recorded. A complete laboratory work-
up was performed every week. Therapy with G-CSF initially
led to a “peak” of WBC and ANC and subsequently to a
normalization for few days (Table 1). No side eﬀects has
been reported by the patient during the treatment and no
adverse eﬀects were noted when the counts were greater than
40 × 103/μL. A reduction of general and oral manifestations
during the neutropenic cycles was constantly recorded. One
week after neutropenic phase periodontal re-evaluation was
carried out in order to assess the plaque control and the
tissutal response to the treatment.International Journal of Dentistry 3
Figure 4: Frontal view of clinical situation at baseline.
Figure 5: Pathological probing depths were recorded at baseline.
A considerable improvement of oral hygiene condi-
tions was observed: FMPS and FMBS remained constantly
≤25% and a period general reduction of probing depth
(PD ≤ 4mm) during the successive 6-month follow-up
was recorded (Figures 7 and 8). Microbiological analysis
was performed. Microbiological sampling included selection
of the deepest periodontal pocket in each quadrant of the
dentitionbasedontheprobingdepthmeasurements.Sample
sites were isolated with cotton rolls and supragingival plaque
was carefully removed with curettes and cotton pallets.
Subsequently, two paper points were inserted to the depth
of the pocket and left in place for 10seconds.
The paper points were transferred to a vial to be send
to the microbiological laboratory in order to perform Poly-
merase Chain Reaction (PCR, Lab Oral International, The
Netherlands). Microbiological analysis revealed no residual
pathogenic subgingival microﬂora but an elevated level of
Fusobacterium nucleatum.
3. Discussion
Cyclic neutropenia (CN) is a chronic rare disorder in the
production of the neutrophils, presenting at about 19–21
days intervals. It is clinically characterized by a periodic
decrease in the circulating neutrophil numbers determining
recurrent infections.
Figure 6: X-ray examination at baseline.
Figure 7: Frontal view of clinical situation after 12-month follow-
up period.
CN is transmitted by autosomal dominant gene and
occurs in infancy but occasionally in adult life [3]. CN is
identiﬁed as an intrinsic defect of granulocyopoiesis, whose
molecularalterationresidesinthegeneofneutrophilelastase
(ELA 2) located on the chromosome 19p13.3.
In the early maturation stage, the mutation of the gene
ELA2 led to an intramedullary apoptosis of neutrophils, that
causes regular phases of neutropenia in peripheral blood
[4]. The neutropenic phases are typically reported to fall in
the range of 19 to 21 days, although recent data indicate
that longer periods occur in some patients. The episodes
last 5–8 days [5]. The diagnostic criterion of CN is absolute
neutrophil count (ANC) less than 0.5×103/μL, at least 3 to 5
consecutive days per cycle, for each of three regularly spaced
cycles.
As a result of neutropenic phases, haematological ﬁnd-
ings could reveal increasing in the number of platelets,
monocytes, lymphocytes, eosinophils, and reticulocytes [6].
Neutropenia predisposes to respiratory or muco-cutaneous
bacterial infection and in some cases was reported in
association with otitis media and upper respiratory infection
[7]. These manifestations are similar, but less severe, to those
commonly reported by patients suﬀering from agranulocy-
tosis. A general malaise, fever, lymphadenopathy, and oral
ulcerations are very common ﬁndings during neutropenic
periods [8]. Severe periodontitis and oral ulcerations have
been reported in the majority of the recorded cases, mean-
while ulcerations may be the unique oral manifestation in
about 20% of patients [9–11]. The mucosal lesions can
aﬀect any part of the oral mucosa during the neutropenic
phases and cause pain and very intense burning that could
discourage the patient to maintain a good oral hygiene.4 International Journal of Dentistry
Table 1: Haematological examinations during G-CSF therapy (March—September 2008).
Date WBC NEUTR LIMPH MONO
(103/μL) (103/μL) (103/μL) (103/μL)
17/03/2008 4.87 1.93 2.5 0.19
24/03/2008 3.13 0.86 1.66 0.35
31/03/2008 2.53 0.15 1.44 0.74
05/04/2008 3.35 0.42 1.78 0.86
20/04/2008 2.8 0.04 1.71 0.92
21/04/2008 Subcutaneous injection of G-CSF
28/04/2008 49.5 43.56 4.16 1.29
06/05/2008 6.44 3.12 2.76 0.32
10/05/2008 4 1.48 2.04 0.36
13/05/2008 3 0.83 1.66 0.39
17/05/2008 2.1 0.05 1.51 0.38
24/05/2008 2.4 0.33 1.29 0.68
29/05/2008 3.43 0.53 1.96 0.66
30/05/2008 Subcutaneous injection of G-CSF
31/05/2008 4.12 1.03 2.51 0.37
04/06/2008 6.4 0.48 2.49 3.17
08/06/2008 48.93 41.39 4.06 2.15
11/06/2008 21.13 16.48 3.4 0.76
15/06/2008 4.3 2.18 1.78 0.21
18/06/2008 3.4 1.52 1.54 0.22
22/06/2008 4.06 1.49 1.8 0.52
27/06/2008 3.2 0.39 1.77 0.97
28/06/2008 Subcutaneous injection of G-CSF
29/06/2008 3.67 0.38 1.82 1.01
02/07/2008 21.57 16.22 3.28 1.27
06/07/2008 19.48 13.56 4.36 0.64
09/07/2008 19.41 14.4 3.98 0.58
13/07/2008 4.4 2.17 1.78 0.34
18/07/2008 3.1 1.32 1.64 0.2
22/07/2008 4.16 1.48 1.7 0.51
27/07/2008 3.1 0.34 1.6 0.99
28/07/2008 Subcutaneous injection of G-CSF
29/07/2008 3.68 0.33 1.8 1.09
02/08/2008 22.47 17.21 3.18 1
06/08/2008 18.47 14.54 4.26 0.54
09/08/2008 18.41 14.43 3.68 0.52
13/08/2008 4.4 2.27 1.88 0.54
17/08/2008 2.8 0.07 1.5 0.35
24/08/2008 2.7 0.35 1.25 0.65
29/08/2008 3.45 0.53 1.88 0.77
30/08/2008 Subcutaneous injection of G-CSF
31/08/2008 5.12 1.33 2.59 0.39
41/91/2008 6.3 0.48 2.47 3.47
08/09/2008 48.93 41.42 4.06 2.26
11/09/2008 22.43 16.18 3.5 0.77
15/09/2008 4.33 2.28 1.79 0.22
WBC: White blood cell count; Neutr: Neutrophil; Limph: Lymphocytes; Mono: Monocytes.International Journal of Dentistry 5
Figure 8: After 12-month follow-up period the periodontal
probing show a PD of 3mm.
Gingivitis is common in CN and severe periodontitis may
aﬀect both deciduous and permanent dentitions [12]. In
the international literature, severe periodontitis is constantly
recorded in subject suﬀering from CN [13–16], meanwhile
this case report is characterized by few periodontal lesions
demonstrating that a signiﬁcant decrease of neutrophil
polymorphonucleate leukocytes could be associated with
moderate periodontal lesions. Medical management of neu-
tropenias is mainly symptomatic and consists of aggressive
antibiotic treatment of febrile patients suspected of having
bacterial infections. Other therapies of uncertain eﬃcacy
include glucocorticoids, androgenic steroids, immunoglobu-
lins,andplasmapheresis[17–21].Inthelastyearstherapeutic
protocols based on the use of recombinant granulocyte
colony-stimulating factor (G-CSF) [22–25] that increases for
few days the number and the function of neutrophils in the
peripheral blood have been proposed by several authors [26–
29].Filgrastimisagranulocytecolony-stimulatingfactor(G-
CSF) analog used to stimulate the proliferation and diﬀer-
entiation of granulocytes. It is produced by recombinant
DNA technology and is only slightly diﬀerent from G-CSF
naturally made in humans. Pegﬁlgrastim is a pegylated form
of Filgrastim: pegylation leads to prolongation of its half-life
without loss of activity [22, 23]. The recent data demonstrate
that Pegﬁlgrastim, at doses ranging from 6 to 12mg alone
or together with chemotherapy, is capable of eﬃciently
mobilizing peripheral blood stem cells, thus resulting in
rapid reconstitution of haematopoiesis. According to data
present in the literature, in which no clinically meaningful
diﬀerence between a single monthly dose of Pegﬁlgrastim
(6mg) and multiple daily doses of Filgrastim (5μg/kg/die)
was recorded, a single dose of G-CSF (Pegﬁlgrastim) was
monthly administered to the patient [30–33], but there are
no organized trials to test or compare Pegﬁlgrastim versus
Filgrastim or other types of G-CSF for treatment of cyclic or
chronic neutropenia.
ThemonthlytherapywithG-CSFcausedarapidincrease
of circulating neutrophils that, even if of short duration,
determined the disappearance of oral ulcerations during
the neutropenic phases. These results conﬁrm the outcomes
found in the literature, in which the use of G-CSF deter-
mined a reduction of oral ulcerations in patient suﬀering
from CN [20]. Moreover the disappearance of ulcerations
determinedanenhancementofthecomplianceofthepatient
who meticulously followed the oral care program.
At 6-month follow-up nonsurgical treatment of the
periodontitis determined a general reduction of probing
depth (PD ≤ 4mm) and a proper tooth brushing leads to an
improvement of oral hygiene resulting in an eﬀective plaque
control by the patient (FMPS ≤ 25%; FMBS ≤ 25%). At
baseline the patient refused to undergo to microbiological
analysis and accepted at 6-month follow-up. At 6-month
follow-up microbiological analysis revealed no residual
pathogenic subgingival microﬂora but an elevated level of
Fusobacterium nucleatum.
Fusobacterium nucleatum is an anaerobic Gram-negative
nonsporeforming oral bacterium found in the normal ﬂora
ofthemouth,thatplaysaroleinperiodontaldisease.Because
of its opportunistic nature, Fusobacterium nucleatum does
not aﬀect the environment directly and is not considered a
major dental pathogen on its own although it can adhere to
a wide range of other organisms, such as Porphyromonas gin-
givalis, and contribute to the development of periodontitis.
Onthebasisofthepresentmicrobiologicalresults,asystemic
antibiotic therapy was not prescribed to the patient. In
conclusion the present results showed that the therapy with
recombinant granulocyte colony-stimulating factor (G-CSF)
allowed the oral mucosa to heal and inﬂuenced the entity
of neutropenic cycle. Moreover the periodontal treatment is
eﬀective in a patient with CN when compliance is suﬃcient
high to follow the maintenance care program.
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